Information de reference pour ce titreAccession Number: | 00130832-200708000-00004.
|
Author: | Chia, Faith L; Leong, Khai Pang
|
Institution: | Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore
|
Title: | |
Source: | Current Opinion in Allergy & Clinical Immunology. 7(4):304-309, August 2007.
|
Abstract: | Purpose of review: This paper updates the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis supported by relevant views about the pathogenesis.
Recent findings: Building on the thesis that Stevens-Johnson syndrome and toxic epidermal necrolysis are due to dermal cell apoptosis, molecular pathways that may lead to this have been proposed. Intravenous immunoglobulin is postulated to block apoptosis via the Fas pathway. Most series on the use of intravenous immunoglobulin in toxic epidermal necrolysis have been favourable. Tumour necrosis factor is also thought to be an important mediator of cell death in toxic epidermal necrolysis. There was impressive control of the progression of toxic epidermal necrolysis with intravenous anti-tumour necrosis factor antibody infliximab in two cases. Strong associations between human leukocyte antigen subtypes and severe cutaneous reactions due to allopurinol and carbamazepine have been described.
Summary: To date, there is no established treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. With advancing knowledge of the pathogenesis, it is hoped that better forms of treatment may result.
Copyright (C) 2007 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | drug allergy; Stevens-Johnson; toxic epidermal necrolysis; treatment.
|
References: | 1 Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600-1607.
2 Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149:1018-1022.
3* Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006; 31:642-647. This report from a country with scarce data on drug allergy confirms that the incidence of severe drug reactions is similar worldwide.
4 Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal anti-inflammatory drugs: a multinational perspective. J Rheumatol 2003; 30:2234-2240.
5 Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors. A case series from prescription-event monitoring In England. Drug Safety 2006; 29:687-696.
6 Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138:1019-1024.
7 Letko GN, Papaliodis DN, Papliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94:419-436.
8 Bircher AJ. Symptoms and dangers signs in drug hypersensitivity. Toxicol 2005; 209:201-207.
9 Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
10 Hung SI, Chung WH, Jee SH. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297-306.
11 Alfirevic A, Jorgensen AL, Williamson PR. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7:813-818.
12 Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome[horizontal ellipsis]: ethnicity matters. Pharmacogenomics J 2006; 6:265-268.
13 Hung SI, Chung WH, Liou BL, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102:4143-4239.
14 Ueta M, Sotozono C, Tokunaga K, et al. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143:367-368.
15* Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort Study. CID 2006; 43:99-102. This is a direct application of the knowledge that HLA-B*5701 is associated with abacavir-induced adverse reactions in HIV patients. By screening for the gene, the authors successfully reduced the incidence of adverse reactions in their cohort.
16* Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006; 55:27-33. This is an expert summary of the knowledge of delayed hypersensitivity reactions accrued over the past decade with postulations on their clinical usefulness.
17 Meth MJ, Sperber KE. Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. Mt Sinai J Med 2006; 73:769-776.
18 Leyva L, Torres MJ, Posadas S, et al. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J Allergy Clin Immunol 2000; 105(1 Pt 1):157-165.
19 Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-1215.
20 Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 2003; 162:1515-1520.
21 Posadas S, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155-161.
22** Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155:722-728. This study extends the knowledge of the range of cytokines and chemokine receptors found in SJS and TEN.
23 Tapia B, Padial A, Sanchez-Sabate E, et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004; 114:335-340.
24 Rodriguez-Pena R, Lopez S, Mayorga C, et al. Potential involvement of dendritic cells in delayed-type hypersensitivity reactions to [beta]-lactams. J Allergy Clin Immunol 2006; 118:949-956.
25 Bastuji-Garin S, Fouchard N, Berochhi M, et al. SCORTEN: A severity of illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149-153.
26 Trent JT, Kirsher RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Derm 2004; 140:890-892.
27** Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126:272-276. The authors describe a predictive tool for a severe drug allergic reaction has been validated. This is an important step for uniform reporting in future trials of TEN therapies.
28 Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens Johnson syndrome; does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136:323-337.
29 Paquet P, Jacob E, Quatresooz P, et al. Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis. Burns 2007; 33:100-104.
30 Palmieri TL, Greenhalgh DG, Sattie JR, et al. A multicentre review of toxic epidermal necrolysis treatment in US burns centres at the end of the twentieth century. J Burn Care Rehabil 2002; 23:87-96.
31 Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clinics in Dermatol 2005; 23:171-181.
32 Halebian PH, Goldfarb IW, Madden MR, et al. Improved burn center survival of toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204:503-512.
33 Paquet P, Pierard GE, Quatrasooz P. Novel treatments for drug induced toxic epidermal necrolysis. Int Arch Allergy Immunol 2005; 136:205-216.
34 Tripathi A, Ditto AM, Grammer LC, et al. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 2000; 21:101-105.
35 Viard L, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-493.
36 Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003; 91:86-91.
37 Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulin: multicentre retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139:26-32.
38* French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55:9-16. This paper contains a careful analysis of the series of patients treated with IVIg.
39* Khalili B, Balma SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 2006; 97:272-280. This paper provides a good review of the management of SJS and TEN, including the various therapies not covered in the previous reference.
40 Bachot N, Revuz J, Rojeau JC. Intravenous immunoglobulin for Stevens Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparitive study showing no benefit on mortality or progression. Arch Dermatol 2003; 139:33-36.
41 Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25:246-255.
42 Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004; 25:81-88.
43 Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30:578-602.
44 Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: Seven cases and review of the literature. Pediatrics 2003; 112:1430-1436.
45 Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47:548-552.
46 Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide vs placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-1589.
47 Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-[alpha] antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146:707-708.
48 Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005; 116:923-924.
49 Arevalo JM, Lorente JA, Gonzalex-Herrada C, et al. Treatment of toxic epidermal necrolysis with cyclosporine A. J Trauma 2000; 48:473-478.
50 Redondo P, Felipe L, Pena A. Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136:645-646.
51 Velez A, Moreno J-C. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol 2002; 46:469-470.
52 Claes P, Wintzen M, Allard S, et al. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine. Eur J Intern Med 2004; 15:255-258.
53 Tas S, Simonart T, Heenen M. Angio-oedema caused by high doses of N-acetylcysteine in patients with anticonvulsant hypersensitivity syndrome. Br J Dermatol 2001; 145:856-857.
54 Walmsley SL, Khorasheh S, Singer J, et al. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pnuemocystis carinii pneumonia prophylaxis (CTN 057) Canadian HIV trials Network 057 Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:498-505.
55 Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens-Johnson syndrome and Toxic epidermal necrolysis. Acute ocular manifestations, causes and management. Corneal 2007; 26:123-129.
56 Power WJ, Choraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of erythema multiforme/Stevens-Johnson syndrome/Toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102:1669-1676.
57 Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007; Feb 19 [Epub ahead of print].
58 Ang LP, Sotozono C, Koizumi N, et al. A comparison between cultivated and conventional limbal stem cell transplantation for Stevens-Johnson syndrome. Am J Ophthalmol 2007; 143:178-180.
59 Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477.
60 Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854-863.
61 Mahapatra M, Mishra P, Kumar R. Imatinib-induced Stevens-Johnson syndrome: after re-challenge with a lower dose [letter]. Ann Hematol 2007; Feb 8 [Epub ahead of print].
62 Pirker C, Misic A, Brinkmeier T, Frosch PJ. Tetrazepam drug sensitivity: usefulness of the patch test. Contact Dermatitis 2002; 47:135-138.
|
Language: | English.
|
Document Type: | Drug allergy.
|
Journal Subset: | Nursing. Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 1528-4050
|
NLM Journal Code: | 100936359
|
DOI Number: | https://dx.doi.org/10.1097/ACI.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|